Search the Newsreel

How Investors May Respond To ANI Pharmaceuticals (ANIP) Record Q2 Results And Reaffirmed 2026 Revenue Guidance

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

ANI Pharmaceuticals, Inc. ANIP topped second-quarter earnings and revenue expectations, but the quarter also exposed a softer result for Cortrophin Gel, its key growth driver. That tension matters because Cortrophin now carries more weight in the company's growth mix. ANI kept its broader 2026 …

The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call

ANI Pharmaceuticals reported strong Q2 year-on-year growth in its rare disease and generics businesses, exceeding analyst estimates for revenue, EPS, and EBITDA, though the market reacted negatively. CEO Nikhil Lalwani highlighted significant momentum in demand for Cortrophin Gel. Analysts focused on the gout expansion, …

ANI Pharmaceuticals (ANIP) Insider Sell: SR. VP, GENERAL COUNSEL & SEC. Meredith Cook Sells 500 Shares

Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals (ANIP), sold 500 shares of the company stock for approximately $37,740. This transaction is part of a broader trend of insider selling at ANI Pharmaceuticals, with 48 insider sells and zero buys over …

ANI Pharmaceuticals (ANIP) counsel Meredith Cook sells 500 shares under 10b5-1 plan

Meredith Cook, Senior Vice President, General Counsel and Secretary at ANI Pharmaceuticals (ANIP), sold 500 shares of common stock at $75.48 per share on August 13, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted in September 2025. Following the sale, …

ANI Pharmaceuticals Senior VP Meredith Cook Sells 500 Shares via 10b5-1 Trading Plan

Meredith Cook, Senior Vice President, General Counsel, and Secretary of ANI Pharmaceuticals Inc (NASDAQ:ANIP), sold 500 shares of the company's common stock on August 13, 2026. The sale, executed under a pre-established Rule 10b5-1 trading plan adopted on September 15, 2025, occurred at a …

Amundi Has $352,000 Holdings in ANI Pharmaceuticals, Inc. $ANIP

Amundi significantly reduced its stake in ANI Pharmaceuticals by 93% in Q1, selling 61,159 shares and retaining 4,571 shares worth $352,000. Despite Amundi's divestment, other institutional investors like Balyasny, Rubric Capital, UBS, and Schonfeld substantially increased their positions, with institutional ownership now at 76.05%. …

Ani Pharmaceuticals SVP Ori Gutwerg sells $243,474 in common stock.

Ori Gutwerg, SVP of Generics at ANI Pharmaceuticals Inc. (NASDAQ:ANIP), sold 3,162 shares of common stock for $243,474 on August 10, 2026. Following the sale, Gutwerg directly holds 75,534 shares. This transaction comes as the company's stock trades near its 52-week low, and after …

ANI Pharma SVP, Generics Ori Gutwerg reports sale of 3,162 common shares worth $243,474

Ori Gutwerg, SVP of Generics at ANI Pharmaceuticals, sold 3,162 common shares for $77 each on August 10, totaling $243,474. This transaction reduced his holdings to 75,534 common shares. The information for this report was generated by AI from an SEC filing.

ANI Pharmaceuticals (ANIP) SVP Ori Gutwerg sells 3,162 shares at $77

Ori Gutwerg, Senior Vice President of Generics at ANI Pharmaceuticals Inc. (ANIP), sold 3,162 shares of common stock at $77.00 per share on August 10, 2026. Following this transaction, Gutwerg directly holds 75,534 shares of the company's common stock. The sale, valued at $243,000, …

ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration

ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 25.9% year on year to $266 million. On the other hand, the company's …

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut

ANI Pharmaceuticals ANIP reported second-quarter 2026 adjusted EPS of $2.21, beating the Zacks Consensus Estimate of $2.01. The reported figure rose 23% year over year, driven by higher sales during the quarter. Quarterly revenues totaled $266 million, up 26% from the year-ago period. The …

Canaccord Genuity Group Cuts ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $90.00

Canaccord Genuity Group has lowered its price target for ANI Pharmaceuticals (NASDAQ:ANIP) to $90.00 from $91.00, while maintaining a "hold" rating. This implies a potential upside of 15% from the previous closing price. The company recently surpassed quarterly earnings expectations, reporting adjusted EPS of …

ANI Pharmaceuticals (ANIP) Stock Slides As Cortrophin Concentration Clouds Profit Quality

ANI Pharmaceuticals (ANIP) Could Be 31% Undervalued On Strong Q2 Results And Guidance Reset

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. ANI Pharmaceuticals earnings beat and guidance reset ANI Pharmaceuticals (ANIP) reported better than expected Q2 2026 results and reaffirmed full year revenue guidance, while trimming its Cortrophin …

ANI Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ANIP) 2026-08-08

ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Transformation and Operational Execution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Wall Street Zen

ANI Pharmaceuticals (NASDAQ:ANIP) recently had its stock rating lowered from "strong buy" to "buy" by Wall Street Zen, though the broader analyst consensus remains a "Moderate Buy" with an average target price of $106.83. This downgrade follows strong second-quarter results where the company exceeded …

Earnings Surge And Reaffirmed 2026 Outlook Might Change The Case For Investing In ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $109.12, Implies 32% Upside

Analysts have revised their average 12-month price target for ANI Pharmaceuticals, Inc. (ANIP) stock down slightly from $110 to $109.12, with a range of $91 to $124. This new target suggests a potential upside of approximately 32% from its August 6th closing price. The …

ANI Pharmaceuticals 2026: Revenue $266.04M, EPS $1.05— 10-Q Summary

ANI Pharmaceuticals reported strong second-quarter 2026 results, with revenue reaching $266.04 million and diluted EPS at $1.05. This growth was primarily driven by significant volume gains in its Rare Disease segment, particularly Cortrophin Gel, and increased generics volume. The company also saw a substantial …

ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Transformation and Operational Execution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Earnings call transcript: ANI Pharmaceuticals beats Q2 2026 estimates, shares fall premarket

ANI Pharmaceuticals reported stronger-than-expected Q2 2026 results, with adjusted EPS of $2.21 and record revenue of $266 million, surpassing analyst estimates. Despite the beat, the stock fell in premarket trading due to investor focus on the company's outlook, declining gross margins, and a revised …

ANI Pharmaceuticals Releases Q2 2026 Financial Results

ANI Pharmaceuticals, Inc. reported strong Q2 2026 financial results, with adjusted diluted EPS of $2.21, beating analyst estimates, and revenue of $266.0M, a 25.9% increase year-over-year. The company's flagship product, Cortrophin Gel, was a key growth driver, and management provided optimistic full-year EPS guidance. …

ANI Pharmaceuticals Inc (ANIP) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ...

This article first appeared on GuruFocus. Release Date: August 07, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Record Q2 2026 revenues of $266 million, up 26% year-over-year, driven by strong performance in …

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

ANI Pharmaceuticals stock falls 7% despite second quarter beat

ANI Pharmaceuticals Inc. reported better-than-expected second-quarter results but saw its stock fall 7.60% in pre-market trading. This decline was primarily due to the company lowering its full-year guidance for its key Cortrophin Gel product, despite reaffirming overall full-year revenue and adjusted EBITDA/EPS guidance. The …

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates

ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance

ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance

Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Reports Q2 Revenue $266.0M, vs. FactSet Est of $260.1M

ANI Pharmaceuticals, Inc. (ANIP) reported its Q2 revenue of $266.0 million, surpassing the FactSet estimate of $260.1 million. The company also announced Q2 adjusted EPS of $2.21 per share, exceeding the FactSet estimate of $2.04. Furthermore, ANI Pharmaceuticals expects 2026 net revenue in the …

Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $2.21 per Share, vs. FactSet Est of $2.04

ANI Pharmaceuticals, Inc. (ANIP) reported Q2 adjusted EPS of $2.21 per share, surpassing FactSet's estimate of $2.04. The company's adjusted earnings and revenue both rose in Q2. Additionally, ANI Pharmaceuticals expects 2026 net revenue to range between $1.08 billion and $1.14 billion and adjusted …

ANI Pharmaceuticals Reports Second-Quarter 2026 Results, Raises Cortrophin Gel Guidance and Reaffirms Full-Year Outlook

ANI Pharmaceuticals earnings on deck as rare disease shift accelerates By Investing.com

ANI Pharmaceuticals is set to report Q2 earnings, with investors focusing on the company's shift towards rare disease treatments, particularly Cortrophin Gel. Analysts predict $2.05 EPS on $260.85 million revenue, and the market will scrutinize Cortrophin's sustained momentum, profitability amidst rising royalties and operating …